Analysts Set InflaRx N.V. (NASDAQ:IFRX) Target Price at $7.50

Shares of InflaRx N.V. (NASDAQ:IFRX) have earned an average rating of “Moderate Buy” from the seven research firms that are covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating on the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $7.50.

Several research analysts have recently weighed in on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of InflaRx in a report on Monday, December 29th. Wall Street Zen lowered InflaRx from a “hold” rating to a “sell” rating in a research note on Saturday, November 8th. Leerink Partners restated a “market perform” rating and issued a $2.00 price objective (down from $5.00) on shares of InflaRx in a report on Wednesday, December 3rd. Guggenheim lifted their price objective on InflaRx from $10.00 to $22.00 and gave the company a “buy” rating in a research note on Monday, November 10th. Finally, Raymond James Financial reissued an “outperform” rating on shares of InflaRx in a research report on Wednesday, December 31st.

InflaRx Stock Up 0.3%

Shares of InflaRx stock opened at $0.92 on Monday. InflaRx has a fifty-two week low of $0.71 and a fifty-two week high of $1.94. The business’s fifty day moving average is $0.96 and its two-hundred day moving average is $1.16. The firm has a market cap of $61.45 million, a PE ratio of -1.35 and a beta of 1.48.

Institutional Investors Weigh In On InflaRx

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Cubist Systematic Strategies LLC raised its position in shares of InflaRx by 33.9% in the 1st quarter. Cubist Systematic Strategies LLC now owns 30,053 shares of the company’s stock valued at $31,000 after purchasing an additional 7,616 shares in the last quarter. HRT Financial LP bought a new position in shares of InflaRx during the fourth quarter valued at approximately $47,000. Concurrent Investment Advisors LLC lifted its stake in InflaRx by 56.9% in the fourth quarter. Concurrent Investment Advisors LLC now owns 52,951 shares of the company’s stock valued at $53,000 after buying an additional 19,200 shares during the last quarter. Insigneo Advisory Services LLC bought a new stake in InflaRx in the 4th quarter valued at about $61,000. Finally, Quadrature Capital Ltd acquired a new position in shares of InflaRx during the fourth quarter worth approximately $104,000. Hedge funds and other institutional investors own 42.39% of the company’s stock.

InflaRx Company Profile

InflaRx N.V. is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies targeting the complement system, with an emphasis on the complement‐1a (C5a) pathway. The company’s lead product candidate, vilobelimab (IFX‐1), is a monoclonal antibody designed to selectively inhibit C5a, a potent pro‐inflammatory peptide implicated in a range of autoimmune and inflammatory diseases. InflaRx seeks to address high‐unmet medical needs by advancing treatments for conditions such as hidradenitis suppurativa, pyoderma gangrenosum and other rare and severe inflammatory disorders.

Vilobelimab has been evaluated in multiple Phase II trials, demonstrating proof of concept in reducing key inflammatory markers and improving clinical outcomes.